References
- Agh T, Inotai A, Meszaros A. 2011. Factors associated with medication adherence in patients with chronic obstructive pulmonary disease. Respiration. 82(4):328–334. doi: 10.1159/000324453.
- Agustí A, Celli BR, Criner GJ, Halpin D, Anzueto A, Barnes P, Bourbeau J, Han MK, Martinez FJ, Montes De Oca M, et al. 2023. Global initiative for chronic obstructive lung disease 2023 report: GOLD executive summary. Am J Respir Crit Care Med. 207(7):819–837. doi: 10.1164/rccm.202301-0106PP.
- Beumer JH, Beijnen JH, Schellens JH. 2006. Mass balance studies, with a focus on anticancer drugs. Clin Pharmacokinet. 45(1):33–58. doi: 10.2165/00003088-200645010-00003.
- Carzaniga L, Linney ID, Rizzi A, Delcanale M, Schmidt W, Knight CK, Pastore F, Miglietta D, Carnini C, Cesari N, et al. 2022. A novel super-soft dual pharmacology muscarinic antagonist and ß2 agonist (MABA) for the inhaled treatment of respiratory diseases. J Med Chem. 65(15):10233–10250.
- Cazzola M, Matera MG. 2008. Novel long‐acting bronchodilators for COPD and asthma. Br J Pharmacol. 155(3):291–299. doi: 10.1038/bjp.2008.284.
- Cazzola M, Page CP, Calzetta L, Matera MG. 2012. Pharmacology and Therapeutics of Bronchodilators. Pharmacol Rev. 64(3):450–504. doi: 10.1124/pr.111.004580.
- Cazzola M, Lopez-Campos JL, Puente-Maestu L. 2013. The MABA approach: a new option to improve bronchodilator therapy. Eur Respir J. 42(4):885–887. doi: 10.1183/09031936.00067013.
- Davies B, Morris T. 1993. Physiological parameters in laboratory animals and humans. Pharm Res. 10(7):1093–1095. doi: 10.1023/a:1018943613122.
- Fabbri LM, Roversi S, Beghé B. 2017. Triple therapy for symptomatic patients with COPD. Lancet. 389(10082):1864–1865. doi: 10.1016/S0140-6736(17)30567-6.
- Gaduzo S, McGovern V, Roberts J, Scullion JE, Singh D. 2019. When to use single-inhaler triple therapy in COPD: a practical approach for primary care health care professionals. Int J Chron Obstruct Pulmon Dis. 14:391–401. doi: 10.2147/COPD.S173901.
- Hoffmann M, Shilling A. 2012. Milk excretion and placental transfer studies. In: Zhang D, Surapaneni S, editors. ADME-enabling technologies in drug design and development. Hoboken (NJ): Wiley.
- Hughes AD, McNamara A, Steinfeld T. 2012. Multivalent dual pharmacology muscarinic antagonist and b2 agonist (MABA) molecules for the treatment of COPD. Prog Med Chem. 51:71–95.
- Kerwin E, Feldman G, Pearle J, De La Cruz L, Edwards M, Beaudot C, Georges G. 2021. Efficacy and safety of inhaled glycopyrronium bromide in COPD: a randomized, parallel group, dose-ranging study (GLIMMER). COPD. 18(2):181–190. doi: 10.1080/15412555.2021.1894111.
- Matera MG, Rogliani P, Calzetta L, Cazzola M. 2020. Triple combination inhalers in chronic obstructive pulmonary disease and asthma. Respir Pulm Dis. 5(1):18–23. doi: 10.17925/USPRD.2020.5.1.18.
- Miglietta D, Carnini C, Bassani F, Tondelli M, Murgo A, Mileo V, Riccardi B, Patacchini R, Maurizio M, Villetti G. 2017. CHF6366: characterisation of the bronchoprotective effect of a novel MABA compound in the experimental bronchospasm model in anaesthetised guinea pigs. Eur Respir J. 50:OA4405. doi: 10.1183/1393003.congress-2017.OA4405.
- Montuschi P, Malerba M, Santini G, Miravitlles M. 2014. Pharmacological treatment of chronic obstructive pulmonary disease: from evidence-based medicine to phenotyping. Drug Discov Today. 19(12):1928–1935. doi: 10.1016/j.drudis.2014.08.004.
- Norel X, Angrisani M, Labat C, Gorenne I, Dulmet E, Rossi F, Brink C. 1993. Degradation of acetylcholine in human airways: role of butyrylcholinesterase. Br J Pharmacol. 108(4):914–919. Aprdoi: 10.1111/j.1476-5381.1993.tb13486.x.
- Page C, Cazzola M. 2014. Bifunctional drugs for the treatment of asthma and chronic obstructive pulmonary disease. Eur Respir J. 44 (2):475–482. doi: 10.1183/09031936.00003814.
- Penner N, Xu L, Prakash C. 2012. Radiolabelled Absorption, Distribution, Metabolism, and Excretion Studies in Drug Development: why, When, and How? Chem Res Toxicol. 25(3):513–531. doi: 10.1021/tx300050f.
- Potchoiba MJ, West M, Nocerini MR. 1998. Quantitative comparison of autoradioluminographic and radiometric tissue distribution studies using carbon-14 labeled xenobiotics. Drug Metab Dispos. 26(3):272–277.
- Rancati F, Linney ID, Rizzi A, Delcanale M, Knight CK, Schmidt W, Pastore F, Riccardi B, Mileo V, Carnini C, et al. 2021. Discovery of a novel class of inhaled dual pharmacology muscarinic antagonist and β2 agonist (MABA) for the treatment of chronic obstructive pulmonary disease (COPD). Bioorg Med Chem Lett. 41:127975.
- Radic’ Z, Taylor P. 2006. Chapter 12, structure and function of cholinesterases. In: Toxicology of organophosphate & carbamate compounds. Cambridge (MA): Academic Press; p. 161–186.
- Shigematsu A, Aihara M, Motoji N, Hatori Y, Hamai Y, Asaumi M, Iwai S, Ogawa M, Miura K. 1999. Proposition for assessment of quantitative whole-body autoradiography. Exp Mol Pathol. 67(2):75–90. doi: 10.1006/exmp.1999.2272.
- Solon EG. 2015. Autoradiography techniques and quantification of drug distribution. Cell Tissue Res. 360(1):87–107. doi: 10.1007/s00441-014-2093-4.
- Steinke W, Archimbaud Y, Becka M, Binder R, Busch U, Dupont P, Maas J. 2000. Quantitative distribution studies in animals: cross-validation of radioluminography versus liquid-scintillation measurement. Regul Toxicol Pharmacol. 31(2 Pt 2):S33–S43. doi: 10.1006/rtph.2000.1384.
- Steinfeld T, Hughes AD, Klein U, Smith JAM, Mammen M. 2011. THRX-198321 is a bifunctional muscarinic receptor antagonist and β2-adrenoceptor agonist (MABA) that binds in a bimodal and multivalent manner. Mol Pharmacol. 79 (3):389–−399. doi: 10.1124/mol.110.069120.
- Ullberg S. 1954. Studies on the distribution and fate of S35-labelled benzylpenicillin in the body. Acta Radiol Suppl. 118:1–110.
- Van der Molen T, Cazzola M. 2012. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination therapy on patient-centred outcomes. Prim Care Respir J. 21(1):101–108. doi: 10.4104/pcrj.2011.00102.
- Waynforth HB, Flecknell PA. 1992. Experimental and surgical techniques in the rat. London (San Diego): Academic Press.
- White RE, Evans DC, Hop CE, Moore DJ, Prakash C, Surapaneni S, Tse FL. 2013. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: a commentary on why they are still necessary. Xenobiotica. 43(2):219–225. doi: 10.3109/00498254.2012.706724.
- Wilson ID, Jeremy K, Nicholson JK. 2017. Gut microbiome interactions with drug metabolism, efficacy, and toxicity. Transl Res. 179:204–222. doi: 10.1016/j.trsl.2016.08.002.
- Yu AP, Guérin A, Ponce de Leon D, Ramakrishnan K, Wu EQ, Mocarski M, Blum S, Setyawan J. 2011. Therapy persistence and adherence in patients with chronic obstructive pulmonary disease: multiple versus single long-acting maintenance inhalers. J Med Econ. 14(4):486–496. doi: 10.3111/13696998.2011.594123.
- Zane PA, Brindle SD, Gause DO, O'Buck AJ, Raghavan PR, Tripp SL. 1990. Physicochemical factors associated with binding and retention of compounds in ocular melanin of rats: correlations using data from whole-body autoradiography and molecular modeling for multiple linear regression analyses. Pharm Res. 7(9):935–941. doi: 10.1023/a:1015997823755.